Sign in Create account

Bal Pharma Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: BALPHARMA BSE: 524824
₹109.53
▼ -2.58 (-2.30%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
22/100
Weak
Valuation
65/100
Fairly Valued
Momentum
87/100
Bullish

QVM read Momentum-led Quality Weak, Valuation Fairly Valued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹174 Cr
PE (TTM)
21.7
Industry median 36.1 (152 companies)
Price to Book
2.1
PEG (TTM)
-7.1
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
40.7
Relative return vs Sector, qtr %
36.2
Free Cash Flow
₹4 Cr
as of Sept. 30, 2025
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
265.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-4.92%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
13.08%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
259.44%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
34.73%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.07
as of March 31, 2025
Industry median 1.84 (197 companies)
Debt to Equity
1.94
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
1.42
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
1.31%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
6.36%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
7.32%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
2.14%
as of March 31, 2025
Industry median 5.54% (180 companies)
Return on Capital Employed
18.93%
as of March 31, 2025
Industry median 12.43% (181 companies)
Return on Equity
7.68%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

0 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (1.94)
  • No Return on equity is 15% or more (7.7%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

3 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.3%
Low 109.0000 · High 113.3800
1W return
1.2%
Low 103.0000 · High 114.6300
1M return
28.9%
Low 84.1000 · High 124.6000
52W return
30.9%
Low 60.0000 · High 124.6000
Lifetime High ₹159.2000 (Jan. 12, 2016)
Lifetime Low ₹13.0000 (June 21, 2013)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
108.5
10D
106.8
20D
102.9
50D
95.7
100D
89.8
200D
80.7

Delivery and volume

Day avg. delivery
57.0%
Week avg. delivery
44.9%
Month avg. delivery
44.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

110.64
Pivot
First resistance112.27
Second resistance115.02
Third resistance116.65
First support107.89
Second support106.26
Third support103.51
Day RSI60.8
Day MFI71.3
Day MACD5.08
Day MACD signal4.90

Beta

1M-0.84
3M-0.29
1Y0.81
3Y0.83

Price change analysis

↑ 28.9%
Over 1 Month
LowHigh
84.10124.60
↑ 36.2%
Over 3 Months
LowHigh
76.01124.60
↑ 68.8%
Over 6 Months
LowHigh
62.16124.60
↑ 30.9%
Over 1 Year
LowHigh
60.00124.60
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 21.7 (own history: 13.4–20.0)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹88 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹0.7300

Ranks #125 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter50.86%
  • FII/FPI0.15%

Largest holders

NameCategoryShares %Shares
SHAILESH SIROYAPromoter17.2400%2745459
Micro Labs LimitedPromoter12.6400%2011736
ANITA SIROYAPromoter6.5900%1049220
Prakash Chandra JainPublic3.4400%548311
Ram Keshav MurthyPublic3.3100%527600

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 50.86% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 0.14% to 0.15% in Jun 2026 qtr

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 26 insider trades, 16 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
13 Apr 2022 SHAILESH SIROYA Promoter Buy 0 ₹0
24 Nov 2021 MICRO LABS LIMITED Other Buy 0 ₹0
27 Aug 2021 MICRO LABS LIMITED Promoter Buy 0 ₹0
22 Mar 2021 SHAILESH SIROYA Promoter Buy 0 ₹0
31 Mar 2020 ANAND SURANA Promoter Buy 0 ₹0
31 Mar 2020 ANITA SIROYA Promoter Buy 0 ₹0
31 Mar 2020 SUBBARAO PRASANNA Promoter Buy 0 ₹0
31 Mar 2020 DILIP SURANA (HUF) Promoter Buy 0 ₹0
31 Mar 2020 MICRO LABS LIMITED Promoter Buy 0 ₹0
31 Mar 2020 DILIP SURANA Promoter Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 270 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
21 Jul 2026 ORION STOCKS LTD Bulk Buy 16,325 89.6900 NSE
21 Jul 2026 ORION STOCKS LTD Bulk Sell 122,544 89.7000 NSE
21 Jul 2026 ORION STOCKS LTD Bulk Sell 8,104 89.8000 BSE
21 Jul 2026 ORION STOCKS LTD Bulk Buy 120,073 89.5800 BSE
4 Apr 2025 PARTH INFIN BROKERS PVT LTD Bulk Sell 110,803 124.3600 NSE
4 Apr 2025 PARTH INFIN BROKERS PVT LTD Bulk Buy 110,803 125.3100 NSE
4 Apr 2025 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Buy 132,023 121.0300 NSE
4 Apr 2025 NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 132,023 121.1700 NSE
4 Apr 2025 MUDUPULAVEMULA SURENDRANADHA REDDY Bulk Buy 123,412 120.9600 NSE
4 Apr 2025 MUDUPULAVEMULA SURENDRANADHA REDDY Bulk Sell 123,412 121.5100 NSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹1.20 per share
Dividend yield 1.10%
Ex-dateSubjectPer share (₹)Record date
17 Sep 2026 Dividend - Rs 1.20 Per Share 1.2000 17 Sep 2026
18 Sep 2025 Dividend - Rs 1.20 Per Share 1.2000 18 Sep 2025
17 Sep 2024 Annual General Me0etingdividend - Rs 1.2 Per Share 1.2000 —
18 Sep 2023 Annual General Meeting/Dividend - Re 1 Per Share 1.0000 —
13 Sep 2022 Annual General Meetingdividend - Re 1 Per Share 1.0000 —
16 Sep 2021 Annual General Meeting/Dividend - Re 1 Per Share 1.0000 —
17 Sep 2019 Annual General Meeting/Dividend - Re 1 Per Share 1.0000 —
14 Sep 2018 Annual General Meeting/Dividend Re 1 Per Share 1.0000 —
14 Sep 2017 Annual General Meeting/Dividend - Re 1/- Per Share 1.0000 —
15 Sep 2016 Annual General Meeting/Dividend Re 1/- Per Share 1.0000 —

Corporate Actions

Full history (21 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
17 Sep 2020OTHER Annual General Meeting
17 Sep 2012OTHERAnnual General Meeting
19 Sep 2011OTHERAnnual General Meeting
23 Sep 2010OTHERAnnual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
12 Aug 2026 Financial Results/Other business matters Yes
27 May 2026 Financial Results/Dividend/Other business matters Yes
11 Feb 2026 Financial Results Yes
12 Nov 2025 Financial Results/Other business matters Yes
11 Aug 2025 Financial Results/Other business matters Yes

Corporate Announcements

All 544 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
25 Sep 2026 Insider Trading / SAST Bal Pharma Ltd - 524824 - Closure of Trading Window
25 Sep 2026 Change in Director(s) Bal Pharma Limited has informed the Exchange regarding Change in Director(s) of the company.
25 Sep 2026 Shareholders meeting Bal Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2026. Further, the company has informed the Exchange regarding voting results.
25 Sep 2026 Trading Window Bal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
25 Sep 2026 AGM/EGM Bal Pharma Ltd - 524824 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
25 Sep 2026 Company Update Bal Pharma Ltd - 524824 - Announcement under Regulation 30 (LODR)-Change in Directorate
24 Sep 2026 Shareholders meeting Bal Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2026
10 Sep 2026 Company Update Bal Pharma Ltd - 524824 - Clarification Regarding Movement In Price
10 Sep 2026 Company Update Bal Pharma Ltd - 524824 - Clarification sought from Bal Pharma Ltd
10 Sep 2026 Price movement Significant movement in price has been observed in Bal Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Bal Pharma Limited has submitted their response.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (34.7%)

Weaknesses

  • Low Return on Equity (7.7%)
  • Thin net profit margin (1.3%)
  • High financial leverage (Debt/Equity 1.94)

Opportunities

Data unavailable.

Threats

  • Weak interest coverage (1.4x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Bal Pharma Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.